Luye Pharma Group Ltd. (HK:2186)
:2186
Want to see HK:2186 full AI Analyst Report?
2186 Stock Chart & Stats
HK$3.02
HK$0.04(1.95%)
At close: 4:00 PM EST
HK$3.02
HK$0.04(1.95%)
Day’s Range― - ―
52-Week RangeHK$1.74 - HK$4.49
Previous CloseN/A
Volume7.60M
Average Volume (3M)38.67M
Market Cap
HK$7.35B
Enterprise ValueHK$12.41B
Total Cash (Recent Filing)HK$8.88B
Total Debt (Recent Filing)HK$9.42B
Price to Earnings (P/E)10.5
Beta0.87
Next Earnings
Aug 27, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding3,994,515,900
10 Day Avg. Volume34,399,920
30 Day Avg. Volume38,673,367
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)0.60
Price to Sales (P/S)1.52
P/FCF Ratio12.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$4.32Price Target Upside43.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.17
Revenue Forecast (FY)HK$6.95B
Bulls Say, Bears Say
Bulls Say
High Profitability MarginsSustained high gross and EBITDA margins indicate durable product-level pricing power and efficient manufacturing. That margin buffer supports reinvestment in R&D and commercialization, helping the company sustain operating profitability even if top-line growth is uneven over the next 2–6 months.
Improving LeverageA materially lower debt-to-equity and larger equity base reduce financial risk and increase capacity for capital allocation. Improved leverage provides more flexibility for funding pipelines, supporting M&A or partnerships without materially raising default or refinancing risk in the medium term.
Diversified Branded Portfolio & ChannelsA multi-therapeutic branded portfolio plus mixed self-operated and partner commercialization reduces single-product dependency and supports market access across geographies. This structural diversification strengthens revenue resilience and long-term market positioning against localized demand shocks.
Bears Say
Sharp Revenue DeclineA severe year-over-year revenue drop materially weakens the top-line base and raises questions about demand durability, product lifecycle timing, or market share loss. If sustained, lower scale can compress fixed-cost leverage and limit the company’s ability to fund growth initiatives over the medium term.
Volatile Free Cash FlowHistoric swings in free cash flow reduce predictability of internal funding for R&D, dividends, or acquisitions. Even with a 2025 rebound, inconsistent cash conversion (FCF conversion ~44% in 2025) limits confidence in steady cash returns and elevates financing risk for multi-year investments.
Low Return On EquityA low ROE despite healthy margins suggests the balance sheet and equity base are not being deployed efficiently to generate shareholder returns. Persistently weak ROE can indicate suboptimal capital allocation or low asset turnover, constraining long-term value creation.
Luye Pharma Group News
2186 FAQ
What was Luye Pharma Group Ltd.’s price range in the past 12 months?
Luye Pharma Group Ltd. lowest stock price was HK$1.74 and its highest was HK$4.49 in the past 12 months.
What is Luye Pharma Group Ltd.’s market cap?
Luye Pharma Group Ltd.’s market cap is HK$7.35B.
When is Luye Pharma Group Ltd.’s upcoming earnings report date?
Luye Pharma Group Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 75 days.
How were Luye Pharma Group Ltd.’s earnings last quarter?
Luye Pharma Group Ltd. released its earnings results on Mar 30, 2026. The company reported HK$0.093 earnings per share for the quarter, the consensus estimate of HK$0.093 by HK$0.
Is Luye Pharma Group Ltd. overvalued?
According to Wall Street analysts Luye Pharma Group Ltd.’s price is currently Undervalued.
Does Luye Pharma Group Ltd. pay dividends?
Luye Pharma Group Ltd. pays a Annually dividend of HK$0.06 which represents an annual dividend yield of N/A. See more information on Luye Pharma Group Ltd. dividends here
What is Luye Pharma Group Ltd.’s EPS estimate?
Luye Pharma Group Ltd.’s EPS estimate is 0.06.
How many shares outstanding does Luye Pharma Group Ltd. have?
Luye Pharma Group Ltd. has 3,994,515,900 shares outstanding.
What happened to Luye Pharma Group Ltd.’s price movement after its last earnings report?
Luye Pharma Group Ltd. reported an EPS of HK$0.093 in its last earnings report, expectations of HK$0.093. Following the earnings report the stock price went up 3.719%.
Which hedge fund is a major shareholder of Luye Pharma Group Ltd.?
Currently, no hedge funds are holding shares in HK:2186
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Luye Pharma Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$4.32 (43.05% Upside)
HK$4.32 (43.05% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.45%
12-Months-Change
Fundamentals
Return on Equity
4.02%
Trailing 12-Months
Asset Growth
15.79%
Trailing 12-Months
Company Description
Luye Pharma Group Ltd.
Luye Pharma Group Ltd. functions as a global investment holding enterprise, focusing on the worldwide development, production, marketing, and sales of pharmaceutical products. The company's diverse portfolio includes several key oncology treatments: Lipusu for ovarian and breast cancers; CMNa, a chemical sensitizer used in cancer radiotherapy; Tiandida, targeting ovarian or non-small cell lung cancer; and Boyounuo, an injectable medication for various cancers and solid tumors. It also offers Yitaida for acute promyelocytic leukemia and liver cancer, and Lutingnuo, a glutathione injection for combating toxicity and injuries from ionizing radiation. Tiandixin serves as an adjuvant therapy for malignant tumors, hydrothorax, ascites, and respiratory infections. In the metabolic and cardiovascular health sector, Luye Pharma provides Xuezhikang, a lipid-regulating drug for hypercholesterolemia; Beitangning, a pioglitazone hydrochloride capsule for blood glucose control; and Beixi, an acarbose capsule for Type 2 diabetes. For neurological conditions and pain management, offerings include Maitongna, indicated for cerebral edema caused by trauma or surgery, and for venous reflux disorders. Transdermal patches such as Rivastigmine are available for Alzheimer's disease, Fentanyl for cancer pain, and Buprenorphine for chronic pain relief. Additionally, Seroquel and Seroquel XR are provided for treating schizophrenia and manic episodes associated with bipolar affective disorders. Rykindo, an injection for schizophrenia, is also part of their neurological therapeutics. Further therapeutic solutions span various conditions: Nuosen for acute upper digestive tract hemorrhage; Sailimai for diarrhea treatment; and the Apleek Transdermal Patch for contraception. Addressing musculoskeletal and inflammatory issues, the company offers Sidinuo for osteoporosis, Glucosamine hydrochloride tablets for osteoarthritis, Oulai (a compound sodium aescinate gel) for localized swelling, Oukai for soft tissue swelling and venous edema, and Fengshiye for pain in bones, joints, and limbs. Beyond product development, Luye Pharma Group actively engages in the distribution and commercialization of its pharmaceutical drugs, along with the manufacturing and sale of biopharmaceutical products. The company was established in 1994 and is headquartered in Yantai, People's Republic of China.
2186 Stock 12 Month Forecast
Average Price Target
HK$4.32
▲(43.05% Upside)
Technical Analysis
CSPC Pharmaceutical Group
―
Zai Lab Ltd
―
Consun Pharmaceutical Group Ltd.
―
Lepu Biopharma Co. Ltd. Class H
―
CStone Pharmaceuticals
―
Options Prices
Currently, No data available
---